Home » Newsletters » BioWorld Science

BioWorld Science

July 29, 2003

View Archived Issues

New benzisoxazole-based LXR agonists under study at Merck

Novel IMP dehydrogenase inhibitors and their use reported by Celltech R&D

Ajinomoto prepares alpha4 integrin inhibitors

Merck patent covers new mGluR5 antagonists for pain, anxiety and other uses

Bayer presents new p38 kinase inhibitors with potential in COPD therapy

Gruenenthal presents new modulators of IL-12 and IL-10 production

Cetuximab monotherapy in advanced renal cell carcinoma

Intercept Blood System inactivates causative agent of SARS

Causal relationship established between VNS Therapy and depression improvement

European approval recommended for Emtriva

PEG-camptothecin advances for gastric and gastroesophageal junction cancers

Phase III induction trial of Antegren fails to meet primary endpoint

New phase II study evaluates COL-3 in rosacea

Avonex ACT trial commences enrollment

First phase of ONTARGET/TRANSCEND program completed

Biotech Holdings plans postmarketing study for Sucanon in Mexico

Enrollment completed in phase IIb at-home study of PT-141

Diovan approved in Switzerland for ACE inhibitor-intolerant heart failure patients

Sanvar registration dossier accepted for filing by FDA

New phase I trial to evaluate lipid-regulating agent ETC-1001

Potent and selective antitumor activity demonstrated for anti-CD30 antibody-drug conjugate

Telomerase inhibitor GRN-163 advances through preclinical testing

CPMP issues positive opinion for Bondronat for metastatic bone disease

Neurocrine Biosciences initiates phase II trial with NBI-5788 in MS patients

NS-2359 enters phase II testing

FDA approves palonosetron for CINV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...